Timeline for supply limits on Novo Nordisk weight-loss drug unclear, US FDA says (updated)

2Seventy Bio

12/09/2023 17:21

(Adds details on shortage in paragraph 2 and background in
paragraph 3 and 4)
       Sept 12 (Reuters) - The U.S. Food and Drug
Administration said on Tuesday it was not clear when supply of
lower doses of Novo Nordisk's  NOVOb.CO  Wegovy would normalize,
backtracking from its earlier estimates to resume supply of the
popular weight-loss drug this month.
    The FDA, in its drug shortage list, listed the 0.25 mg, 0.5
mg and 1 mg doses of the drug with limited availability and that
the duration of shortage was "to be decided", while the larger
doses of 1.7 mg and 2.4 mg were still available.
    Novo Nordisk CEO Lars Fruergaard Jorgense said last month
the company's limits on U.S. supplies of starter doses of Wegovy
will last into next year even as the Danish drugmaker spends
billions boosting output to keep up with soaring demand.
       The drug was approved for chronic weight management in
people with obesity in 2021.

 (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini
Ganguli)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))